For this study, peripheral blood samples were collected from human volunteers. Mononuclear cells (MNC) were separated by density centrifugation and were induced to differentiate into endothelial progenitor cells (EPCs) in vitro. Different concentrations of rapamycin and silymarin were introduced to the EPCs over 24 hours and then EPCs were analyzed for proliferation, migration, apoptosis and angiogenesis. Compared with the control group, rapamycin (1, 10, 100 ng/mL) inhibited the proliferation and migration of EPCs in a concentration dependent manner (P<0.05). Silymarin (50, 100 µg/mL) enhanced the proliferation and migration of EPCs and inhibited apoptosis in a concentration dependent manner (P<0.05). By adding rapamycin (1 ng/mL) and silymarin (25, 50, 100 µg/mL) over 24 hours, silymarin inhibited the pro-apoptotic effect of rapamycin on EPCs, and reversed the inhibition of proliferation, migration and angiogenesis of EPCs by rapamycin (P<0.05).
Endothelial progenitor cells (EPCs) are the precursor cells that can proliferate and differentiate into vascular endothelial cells. Through either the mobilization or transplantation of EPCs, they are able to repair damaged endothelial cells, and therefore have become one of the new approaches for the treatment of ischemic diseases. Rapamycin-coated stents inhibit DNA synthesis and proliferation of vascular smooth muscles after percutaneous coronary intervention (PCI) and prevent restenosis. However, the inhibition of vascular re-endothelialization of rapamycin and thrombus formation can affect the long-term prognosis of patients with a stent. The mechanism may be rapamycin inhibition of EPCs migration, proliferation, and integration into the intima. Recent studies [1] have found that silymarin can inhibit EPCs senescence and reduce the anti-proliferative effect of rapamycin on EPCs. However, whether silymarin can also improve other inhibitory effects of rapamycin on EPCs is unclear. In the present study, we investigated the impact of rapamycin and silymarin on EPCs proliferation, migration and apoptosis. Additionally, we studied the ability of silymarin to protect EPCs under rapamycin intervention to further optimize the therapeutic effect of EPCs, and reduce thrombotic events after drug-eluting stent implantation.
After one day of growth ( Figure 1a ), cells began to become adherent. An EPCs-specific colony appeared at 3 days ( Figure 1b ). Several colonies formed a cluster of round cells with spindle-shaped cells at the periphery, which appeared after 7 days ( Figure 1c ). Approximately 80% of the cells were positively stained with UEA-I and took up Dil-ac-LDL on the 7th day. Endothelial progenitor identity was confirmed by fluorescent-activated cell sorting (FACS), with antibodies recognizing PE-Mouse anti-human VEGF-R2 monoclonal antibodies, PE-Mouse anti-human CD133 monoclonal antibodies and FITC-Mouse anti-human CD34 monoclonal antibodies. The expression profile of cultured EPCs Peripheral blood mononuclear cell samples were obtained from healthy volunteers. 
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Stimulation with rapamycin for 24 hours decreased EPCs proliferation and migration in a dose-dependent manner (1~100 ng/mL). The proliferation and migration of EPCs in the low concentration group (0.1 ng/mL) showed no significant difference compared with the control group. Stimulation with 1 ng/mL rapamycin decreased EPCs proliferation and migration in a timedependent manner (6 ~48 h). Stimulation with silymarin for 24 hours increased EPCs proliferation and migration in a dose-dependent manner (50~100 µg/mL). The low concentration group (25 µg/mL) was not significantly different from the control group. Stimulation with silymarin for 24 hours decreased EPCs apoptosis in a dosedependent manner (25~100 µg/mL).
When compared with the control group, rapamycin (1 ng/mL) inhibited the proliferation, migration and angiogenesis of EPCs. Silymarin reversed the inhibition of rapamycin on proliferation, migration and angiogenesis of EPCs in a dose-dependent manner (50~100 µg/mL). Rapamycin (1 ng/mL) increased the apoptosis of EPCs, and silymarin inhibited the pro-apoptotic role of rapamycin on EPCs in a concentration dependent manner (25~100 µg/mL). EPCs repair and replace the abnormal endothelial cells through mobilizing and homing on to the injured arterial balloon [2] [3] [4] , while rapamycin is able to hinder proliferation ability of mature endothelial cells. Likewise, rapamycin can accelerate the senescence process of EPCs and enable their dysfunction. It is likely that hindering EPCs and mature endothelial cells will lead to continuously delayed re-endothelialization and wound healing after the stents are inserted. The results of our experiments show that rapamycin has noticeable effects on hindering EPCs proliferation and migration and the effects depend on concentration and time.
The exact mechanism causing rapamycin to accelerate the aging process of EPCs is yet to be determined. Currently, a great deal of research has been focused on telomerase, which is a complex composed of protein and RNA. The RNA has a template sequence, which guides the synthesis of the repeat sequence fragments in the telomerase DNA [5, 6] . There are two important components in the adjustment of telomerase in the normal somatic cells; telomerase RNA template (hTER) [7] and telomerase reverse transcriptase (hTERT) [8] . The hTERT-mRNA and the expressive activity of telomerase correlate well in the extracts of normal cells, as well as cancer cells [9] . Toshio's [10] research demonstrates how rapamycin can decrease EPCs telomerase activity through reducing hTERT-mRNA so that the aging and hypofunction of EPCs can be induced. In addition, Murasawa et al. [11] found that overexpression of hTERT adenovirus may delay the aging of EPCs and restore their regeneration capabilities. Therefore, rapamycin may accelerate ERC telomerase inactivation and aging through inducing hTERT gene expression. Protective effect of silymarin in endothelial progenitor cells Natural Product Communications Vol. 10 (2) 2015 265 a: Positive cells were stained b: Positive cells were stained c: Double-positive cells red by Dil-ac-LDL green by FITC-UEA-1 were stained yellow by both Figure 3 : Results of double fluorescence staining (×200). a, Fluorescence microscopy illustrates that adherent cells were positive for uptake of DiI-ac-LDL. b. Binding of FITC-UEA-1. c. acLDL (+) cells were also positive for ulex-lectin binding. Silymarin is a type of flavonolignan compound extracted from the seed capsule of Silybum marianum. It is mainly used to protect the liver. Recent research has discovered that silymarin has the ability to reduce fat in the blood, reduce the amount of antioxidants, prevent diabetes, protect the heart muscle, and antiplatelet and antineoplastic functions [12] . The results of these experiments demonstrate how the introduction of silymarin increased both proliferative activity and migratory activity of cultured EPCs. Silymarin delivered in 50 µg/mL and 100 µg/mL increased EPCs proliferative activity, although there is no statistical difference. In the apoptosis tests, silymarin at 25 µg/mL~100 µg/mL noticeably hindered apoptosis of the EPCs, while the reduction was dependent on silymarin concentration.
Hong et al. [13] found that silymarin can repair heart muscles damaged by oxygen-glucose deprivation. The caspase and Bcl-2 families play an important role in the process of apoptosis [14] . Li et al. [15] found that silymarin can hinder the activity of caspase-3 and caspase-9 induced by ultraviolet radiation, and thus can hinder the apoptosis of cells. This is achieved by increasing the expression of mitochondrial antiapoptotic protein Bcl-2 and BCL-xl. Recently, Patel et al. [16] verified that silymarin can also hinder the expression of P53 protein on liver cells in order to prevent the apoptosis of these cells. The research literature used for this study provides evidence that silymarin is able to increase the cell's proliferative activity and reduce its apoptosis.
Our study also found that through the intervention of rapamycin, the proliferative activity and migratory activity of cultured cells are significantly reduced. The usage of silymarin can reverse this change and can improve the situation depending on the dosage. Silymarin at 50 µg/mL and 100 µg/mL can noticeably improve the inhibitory effects exerted by rapamycin to EPCs. However, compared with 50 µg/mL, 100 µg/mL silymarin can increase proliferative activity and migratory activity of EPCs, but there is no statistically significant difference, which is consistent with the research findings that only separate silymarin is used. Therefore, we assume that 50 µg/mL silymarin is a proper dosage. This research also demonstrated how rapamycin resisted proliferation of EPCs, which also influenced the angiogenesis of EPCs. The addition of silymarin can, to some degree, restore angiogenesis of EPCs; however, further research is needed to analyze silyamarin's effects on hindering EPCs anti-proliferation caused by rapamycin and its effects on repairing injured blood vessels.
Experimental
Cells: EPCs were prepared as reported previously [17] [18] [19] . Peripheral blood mononuclear cells were isolated from the blood of healthy volunteers using Ficoll density gradient centrifugation. Cells were plated in fibronectin (Sigma, USA) coated 6-well tissue culture plates (10 6 per well) and were incubated in M199 medium supplemented with rh-VEGF (20 ng/mL), rh-b-FGF (50 ng/mL) and IGF (50 ng/mL). After 3 days in culture, non-adherent cells were washed away and the medium was replaced. After 7 days, cells were synchronized with a serum free medium for 24 h [17] , and then treated with either silymarin or rapamycin or both.
Flow cytometry:
The apoptosis of EPCs was investigated using the Annexin V-FITC Apoptosis Detection Kit, according to the manufacturer's protocol. The cells were stained with Annexin-V-FITC and propidium iodide (PI) in a 1× binding buffer for 15 min at room temperature. The relative amount of FITC+ PI− cell populations were used to estimate the proportion of apoptotic cells. Flow cytometric analyses were performed on a Coulter FC-500 flow cytometer.
Matrigel assays: EPCs treated with silymarin and/or rapamycin were seeded on 24-well plates coated with Matrigel, according to the manufacturer's instructions. Network formation images were observed using an inverted phase contrast microscope equipped with a digital camera.
Statistical analysis:
All data were expressed as mean± SD. A oneway ANOVA was used to analyze the differences among the variables. Differences were considered to be significant if the P value < 0.05. All statistical analyses were performed using the statistical software SPSS 18.0.
